Major depressive disorder. Major Depressive episode
Conditions
Interventions
Intervention 1: Capsule Rifampine(900 mg/day in individuals with 75 kg weight or more and 600 mg/day in individuals with weight less than 75 kg)+ Cap. Doxycycline(100 mg bid)+ cap. celecoxib(200 mg bi
Treatment - Drugs
Placebo
Capsule Rifampine(900 mg/day in individuals with 75 kg weight or more and 600 mg/day in individuals with weight less than 75 kg)+ Cap. Doxycycline(100 mg bid)+ cap. celecoxib(200 mg bid) for 8 weeks
Capsule Rifampine(900 mg/day in individuals with 75 kg weight or more and 600 mg/day in individuals with weight less than 75 kg)+ Cap. Doxycycline(100 mg bid)+ cap. placebo for 8 weeks
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1-Confirmation of brucellusis, 2age between 18 to 50 years old, 3- score lower than 20 in Hamilton Rating Scale for depression 4-Mild to moderate major depressive disorder based on DSM-V Exclusion criteria: 1-duration of brucellosis more than 3 months, 2-presence of localized brucellosis(including endocarditis, osteomyelitis), 3-psychotic disorder, 4-receiving psychotropic medications, 5-receiving antidepressants during the last month 6-receiving antibiotics during the last month, 7-patients who are under treatment with immunosuppressives, 8-history of cardiovascular disease, 9-pregnancy, 10-nursing women, 11-any significant medical condition(including malignancy, HIV infection, autoimmune disease,renal failure,hepatic failure), 12- other infectious diseases
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of depression. Timepoint: Baseline and weeks 2-4-8 after beginig of treatment. Method of measurement: by Hamiltion Depression Rating Scale 17-Item. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactProf. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed